RedHill Biopharma Ltd. (NASDAQ:RDHL) saw an upside of 8.47% on Monday at $4.74 after adding $0.37. The 5-day average trading volume is 1,611,003 shares of the company’s common stock. It has gained $5.39 in the past week and touched a new high 2 times within the past 5 days. An average of 1,356,836 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,078,740.
RDHL’s 1-month performance is -57.82% or -$4.61 on its low of $4.14 reached on 09/30/21. The company’s shares have touched a 52-week low of $4.14 and high of $11.52, with the stock’s rally to the 52-week high happening on 02/22/21. YTD, RDHL has lost -45.92% or -$3.20 and has reached a new high 11 times. However, the current price is down -58.85%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
RedHill Biopharma Ltd. (RDHL) has a trailing price-to-earnings (P/E) ratio of 24.12 for the broader industry and 32.16 for the sector, meaning that investors are optimistic about the stock’s future prospects.RDHL stock has a beta of 1.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.53 while the price-to-book (PB) in the most recent quarter is 6.94.
RedHill Biopharma Ltd.’s quick ratio for the period ended June 29 was 1.10, with the current ratio over the same period at 1.20 meaning that RDHL stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.91, while the total debt to equity was 2.97. In terms of profitability, the gross margin trailing 12 months is 50.50%The trailing 12-month EBITDA margin is -85.36% while for the period ending June 29; RedHill Biopharma Ltd.’s operating margin was -91.40%. The firm’s gross profit as reported stood at $27.47 million against revenue of $64.36 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 90.23% to $64.36 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected RDHL to announce -$0.12 per share in earnings in its latest quarter, but it posted -$0.6, representing a -400.00% surprise. EBITDA for the quarter stood at more than -$24.42 million. RDHL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 174.09 million, with total debt at $87.83 million
Let’s look briefly at RedHill Biopharma Ltd. (RDHL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 39.81% to suggest the stock is trending Neutral, with historical volatility in this time period at 82.34%.
The stock’s 5-day moving average is $4.64, reflecting a -5.08% or -$0.26 change from its current price. RDHL is currently trading -48.59% above its 20-day SMA, -20.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -29.60% and -45.79% respectively.
Stochastic %K and %D was 30.13% and 15.97% and the average true range (ATR) pointed at 0.53. The RSI (14) points at 38.44%, while the 14-day stochastic is at 59.32% with the period’s ATR at 0.55. The stock’s 9-day MACD Oscillator is pointing at -0.17 and -0.17 on the 14-day charts.
In the most recent analyst report for RedHill Biopharma Ltd. (NASDAQ: RDHL), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for RDHL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RDHL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is RDHL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $11.50 and a high of $26.00, with their median price target at $21.00. Looking at these predictions, the average price target given by analysts is for RedHill Biopharma Ltd. (RDHL) stock is $18.79.